A $1bn Biosimilar? Amgen Enjoying Early Monopoly On Aflibercept Competition

Firm Eyeing $4bn Biosimilar Offering By 2030; US Soliris Biosimilar Launch Imminent

 
• By Dean Rudge

Amgen’s biosimilar sales grew by 16% last year, and with multiple candidates either due to launch or in the clinic, the firm is showing no signs of slowing down on its aspirations.

Economic recovery and growing wealth business metaphor as a group of trees shaped as a dollar sign growing leaves and bearing fruit as a symbol of wealth and financial success in a growth industry.

More from Earnings

More from Products